Anticoagulation for Atrial Fibrillation : Is This the End of Warfarin? Not Just Yet

Abstract EN

Atrial fibrillation (AF) is the most common cardiac arrhythmia.

Its prevalence is known to increase with age and with an aging population AF is likely to become even more common.

Although sometimes patients with AF remain asymptomatic, it is now recognized that AF is far from “benign” conferring a significant risk increase in morbidity and mortality.

Restoration of sinus rhythm and rate-limiting medication help with symptoms; however, anticoagulation remains essential in reducing thromboembolic risk.

The uptake of appropriate anticoagulation with vitamin K antagonists has increased significantly in the last few decades and this review will analyze whether the new oral anticoagulants might prove to be even more effective than existing vitamin K antagonists.